Volume 30, Issue 3 (Avicenna Journal of Clinical Medicine-Autumn 2023)
Avicenna J Clin Med 2023, 30(3): 173-178 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mohammadi F, Razzaghi M, Talebi S S, Khazaei S, Karimi S A. Investigating the Status of Antiphospholipid Antibodies in Patients with Mild COVID-19. Avicenna J Clin Med 2023; 30 (3) :173-178
URL: http://sjh.umsha.ac.ir/article-1-2832-en.html
URL: http://sjh.umsha.ac.ir/article-1-2832-en.html
1- Clinical Research Development Unit, Shahid Beheshti Hospital, Hamadan University of Medical Sciences, Hamadan, Iran
2- Clinical Research Development Unit, Besat Hospital, Hamadan University of Medical Sciences, Hamadan, Iran ,dr.razzaghi2020@gmail.com
3- Autism Spectrum Disorders Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
4- Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
2- Clinical Research Development Unit, Besat Hospital, Hamadan University of Medical Sciences, Hamadan, Iran ,
3- Autism Spectrum Disorders Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
4- Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
Abstract: (816 Views)
Background and Objective: COVID-19 disease has various manifestations, such as fever, sore throat, shortness of breath, body pain, and loss of consciousness. This disease may cause coagulation disorders and therefore an increase in thromboembolic events in these patients. This study examines the status of anti-phospholipid antibodies (aPL) in such patients, as one of the factors of increased coagulability.
Materials and Methods: This case-control study examined anti-phospholipid antibodies (including lupus anticoagulant, anti-cardiolipin antibody, and anti-beta-2 glycoprotein antibody) in 60 patients with definite mild COVID-19. Patients were included in the study if they met the inclusion criteria. The blood samples of the studied subjects were analyzed in the unit's laboratory. The patients' sample results were compared to those of 60 healthy individuals who were matched in terms of age and gender.
Results: The mean age scores of the case and control groups were 48.54±15.29 and 46.91±16.71 years, respectively (P=0.57). In case group, the Anti-β2GPI (IgG and IgM) test was positive in two patients (P=0.578 and P=0.346). The LAC test was positive in 3 patients and 2 controls (P=0.57). Anti-cardiolipin antibodies was positive in 4 patients (IgG in 1 patient and IgM in 3 patients), compared to the control group in 1 patient (P=0.004).
Conclusion: According to the results of this study, the prevalence of aPL was higher in patients with mild COVID-19 than in healthy individuals. Considering the role of aPL in thrombosis, it may increase the coagulability conditions in these patients.
Materials and Methods: This case-control study examined anti-phospholipid antibodies (including lupus anticoagulant, anti-cardiolipin antibody, and anti-beta-2 glycoprotein antibody) in 60 patients with definite mild COVID-19. Patients were included in the study if they met the inclusion criteria. The blood samples of the studied subjects were analyzed in the unit's laboratory. The patients' sample results were compared to those of 60 healthy individuals who were matched in terms of age and gender.
Results: The mean age scores of the case and control groups were 48.54±15.29 and 46.91±16.71 years, respectively (P=0.57). In case group, the Anti-β2GPI (IgG and IgM) test was positive in two patients (P=0.578 and P=0.346). The LAC test was positive in 3 patients and 2 controls (P=0.57). Anti-cardiolipin antibodies was positive in 4 patients (IgG in 1 patient and IgM in 3 patients), compared to the control group in 1 patient (P=0.004).
Conclusion: According to the results of this study, the prevalence of aPL was higher in patients with mild COVID-19 than in healthy individuals. Considering the role of aPL in thrombosis, it may increase the coagulability conditions in these patients.
Keywords: Anti-beta 2 Glycoprotein Antibody, Anti-Cardiolipin Antibody, Anti-Glycoprotein Antibody, Anti-Phospholipid Antibody, COVID-19
Type of Study: Original |
Subject:
Infectious Diseases
Extended Abstract [HTML 26 KB] (35 Download)
References
1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020; 395(10223):497-506. DOI: 10.1016/S0140-6736(20)30183-5
2. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14. PMID:32353746 DOI: 10.1016/j.thromres.2020.04.024
3. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(6):1421-1424. PMID: 32271988 DOI: 10.1111/jth.14830
4. Klok F, Kruip M, Van der Meer N, Arbous M, Gommers D, Kant K, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-7. PMID: 32291094 DOI: 10.1016/j.thromres.2020.04.013
5. Triplett DA. Antiphospholipid antibodies. Archives of pathology laboratory medicine. 2002; 126(11):1424-9. DOI: 10.5858/2002-126-1424-AA
6. Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, Charney AW, Narula J, Fayad ZA, Bagiella E, Zhao S. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020 ;76(1):122-4. PMID: 32387623 DOI: 10.1016/j.jacc.2020.05.001
7. Harzallah I, Debliquis A, Drénou B. Lupus anticoagulant is frequent in patients with Covid‐19: Response to Reply. J Thromb Haemost. 2020;18(9):E3-E4. PMID:32608109 DOI: 10.1111/jth.14980
8. van der Linden J, Almskog L, Liliequist A, Grip J, Fux T, Rysz S, et al. Thromboembolism, hypercoagulopathy, and antiphospholipid antibodies in critically ill coronavirus disease 2019 patients: a before and after study of enhanced anticoagulation. Crit Care Explor. 2020; 2(12). PMID: 33364605 DOI: 10.1097/CCE.0000000000000308
9. Hamadé A, Woehl B, Harzallah I, Talbot M, Tousch J, Jambert L. Antiphospholipid antibodies in patients with coronavirus disease 2019 infection hospitalized in conventional unit. Blood Coagul Fibrinolysis. 2021; 32(2):73-9. PMID: 33273262 DOI: 10.1097/MBC.0000000000000963
10. Galeano-Valle F, Oblitas C, Ferreiro-Mazón M, Alonso-Muñoz J, Del Toro-Cervera J, Di Natale M, et al. Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb Res. 2020;192:113-115. PMID: 32425261 DOI: 10.1016/j.thromres.2020.05.017
11. Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients. J Thromb Haemost. 2020;18(7):1743-6. PMID: 32320517 DOI: 10.1111/jth.14869
13. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382(17):e38. PMID: 32268022 DOI: 10.1056/NEJMc2007575
14. Hasan Ali O, Bomze D, Risch L. Severe COVID-19 is associated with elevated serum IgA and antiphospholipid IgA-antibodies [Internet]. Clin Infect Dis. 2020. DOI: 10.1101.2020.07.21.20159244
15. Hasan Ali O, Bomze D, Risch L, Brugger SD, Paprotny M, Weber M, et al. Severe Coronavirus Disease 2019 [COVID-19] is Associated With Elevated Serum Immunoglobulin [Ig] A and Antiphospholipid IgA Antibodies. Clin Infect Dis. 2021; 73(9):e2869-e2874. PMID: 32997739 DOI: 10.1093/cid/ciaa1496
16. Siguret V, Voicu S, Neuwirth M, Delrue M, Gayat E, Stépanian A, et al. Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients? Thromb Res. 2020;195:74-6. PMID: 32663703 DOI: 10.1016/j.thromres.2020.07.016
17. Najim M, Rahhal A, Khir F, Aljundi AH, Yousef SA, Ibrahim F, et al. Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study. Rheumatol Int. 2021;41(7):1243-52. PMID: 33954813 DOI: 10.1007/s00296-021-04875-7
18. Gendron N, Dragon‐Durey MA, Chocron R, Darnige L, Jourdi G, Philippe A, et al. Lupus anticoagulant single positivity at acute phase is not associated with venous thromboembolism or in‐hospital mortality in COVID‐19. Arthritis Rheumatol. 2021;73(11):1976-1985. PMID: 33881229 DOI: 10.1002/art.41777
19. Foret T, Dufrost V, Salomon Du Mont L, Costa P, Lefevre B, Lacolley P, et al. systematic review of antiphospholipid antibodies in COVID-19 patients: culprits or bystanders? Curr Rheumatol Rep. 2021;23(8):65. PMID: 34218350 DOI: 10.1007/s11926-021-01029-3
20. Devreese KM. Testing for antiphospholipid antibodies: Advances and best practices. Int J Lab Hematol. 2020;42:49-58. PMID: 32543059 DOI: 10.1111/ijlh.13195
21. Connell NT, Battinelli EM, Connors JM. Coagulopathy of COVID-19 and antiphospholipid antibodies. J Thromb Haemost. 2020;18(9):E1-E2. PMID: 32379918 DOI: 10.1111/jth.14893
22. Sidelmann JJ, Sjøland JA, Gram J, Bertelsen V, Mourits‐Andersen T, Münster H, et al. Lupus anticoagulant is significantly associated with inflammatory reactions in patients with suspected deep vein thrombosis. Scand J Clin Lab Invest. 2007;67(3):270-9. PMID: 17454841 DOI: 10.1080/00365510601038992
23. Schouwers SM, Delanghe JR, Devreese KM. Lupus Anticoagulant [LAC] testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results? Thromb Res. 2010;125(1):102-4. PMID: 19782388 DOI: 10.1016/j.thromres.2009.09.001
24. Seheult JN, Meyer MP, Bontempo FA, Chibisov I. The effects of indirect-and direct-acting anticoagulants on lupus anticoagulant assays: a large, retrospective study at a coagulation reference laboratory. Am J Clin Pathol. 2017;147(6):632-40. PMID: 28525532 DOI: 10.1093/ajcp/aqx035
25. Pengo V, Tripodi A, Reber G, Rand J, Ortel T, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009;7(10):1737-40. PMID:19624461 DOI: 10.1111/j.1538-7836.2009.03555.x
26. Goldman-Mazur S, Wypasek E, Karpiński M, Stanisz A, Undas A. High detection rates of antithrombin deficiency and antiphospholipid syndrome in outpatients aged over 50 years using the standardized protocol for thrombophilia screening. Thromb Res. 2019;176:67-73. PMID: 30780006 DOI: 10.1016/j.thromres.2019.02.008
27. Pengo V, Del Ross T, Ruffatti A, Bison E, Cattini M, Pontara E, et al. Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns. Thromb Res. 2018;172:172-8. PMID: 30466070 DOI: 10.1016/j.thromres.2018.11.003
28. Selmi C, De Santis M, Battezzati PM, Generali E, Lari SA, Ceribelli A, et al. Anti-phospholipid antibody prevalence and association with subclinical atherosclerosis and atherothrombosis in the general population. International journal of cardiology. 2020;300:209-13. DOI: 10.1016/j.ijcard.2019.10.042
29. Asherson R, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis. 2003;62(5):388-93. PMID:12695147 DOI: 10.1136/ard.62.5.388
30. Wenzel C, Stoiser B, Locker GJ, Laczika K, Quehenberger P, Kapiotis S, et al. Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. Crit Care Med. 2002;30(4):763-70. PMID:11940742 DOI:10.1097/00003246-200204000-00007
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s).
Owned by Hamadan University of Medical Sciences
Published by UMSHA Press
Journal Tel: +988138380924
Publisher Tel:+988138380548
Website: http://sjh.umsha.ac.ir
Email: s_ journal[at]umsha.ac.ir
